|
Mar 8
|
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
|
|
Mar 7
|
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
|
|
Jan 14
|
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
|
|
Jan 9
|
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
|
|
Dec 20
|
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 12
|
How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01%
|
|
Dec 1
|
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
|
|
Nov 8
|
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
|
|
Nov 8
|
Castle Biosciences to Present at Upcoming Investor Conferences
|
|
Nov 4
|
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
Q3 2023 Castle Biosciences Inc Earnings Call
|
|
Nov 3
|
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
|
|
Nov 2
|
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings
|
|
Nov 2
|
Castle Biosciences Inc (CSTL) Reports 66% Revenue Increase in Q3 2023
|
|
Nov 2
|
Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
|
|
Nov 2
|
Castle Biosciences Reports Third Quarter 2023 Results
|
|
Oct 19
|
Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
|
|
Oct 18
|
New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
|
|
Aug 7
|
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
|
|
May 3
|
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
|